Growth Metrics

Scholar Rock Holding (SRRK) Depreciation & Amortization (CF) (2017 - 2026)

Scholar Rock Holding's quarterly Depreciation & Amortization (CF) came in at $335000.0 in Q1 2026, down 14.76% year-on-year from $393000.0 in Q1 2025, and down 28.27% quarter-over-quarter from $467000.0 in Q4 2025.

Scholar Rock Holding has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $335000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 14.76% year-over-year to $335000.0; the trailing twelve-month figure through Mar 2026 stood at $1.6 million (down 5.31% YoY), and the FY2025 full-year result was $1.7 million, down 12.24% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $335000.0, down from $467000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $763000.0 in Q4 2022, with the low at $335000.0 in Q1 2026.
  • Average Depreciation & Amortization (CF) over 5 years is $577529.4, with a median of $598000.0 recorded in 2024.
  • Year-over-year, Depreciation & Amortization (CF) rose 26.95% in 2022 and sank 41.22% in 2024.
  • Tracing SRRK's Depreciation & Amortization (CF) over 5 years: stood at $763000.0 in 2022, then slipped by 11.93% to $672000.0 in 2023, then slumped by 41.22% to $395000.0 in 2024, then gained by 18.23% to $467000.0 in 2025, then slipped by 28.27% to $335000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $335000.0 (Q1 2026), $467000.0 (Q4 2025), and $423000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Scholar Rock Holding 500.61 Mn 20.67 Mn - 335,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 335,000.00
Mar 31, 2026 335,000.00
Dec 31, 2025 467,000.00
Dec 31, 2025 467,000.00
Sep 30, 2025 423,000.00
Sep 30, 2025 423,000.00
Jun 30, 2025 417,000.00
Jun 30, 2025 417,000.00
Mar 31, 2025 393,000.00
Mar 31, 2025 393,000.00
Dec 31, 2024 395,000.00
Dec 31, 2024 395,000.00
Sep 30, 2024 446,000.00
Sep 30, 2024 446,000.00
Jun 30, 2024 500,000.00
Jun 30, 2024 500,000.00
Mar 31, 2024 598,000.00
Mar 31, 2024 598,000.00
Dec 31, 2023 672,000.00
Dec 31, 2023 672,000.00
Sep 30, 2023 708,000.00
Sep 30, 2023 708,000.00
Jun 30, 2023 731,000.00
Jun 30, 2023 731,000.00
Mar 31, 2023 733,000.00
Mar 31, 2023 733,000.00
Dec 31, 2022 763,000.00
Dec 31, 2022 763,000.00
Sep 30, 2022 744,000.00
Sep 30, 2022 744,000.00
Jun 30, 2022 744,000.00
Jun 30, 2022 744,000.00
Mar 31, 2022 749,000.00
Mar 31, 2022 749,000.00
Dec 31, 2021 727,000.00
Dec 31, 2021 727,000.00
Sep 30, 2021 673,000.00
Sep 30, 2021 673,000.00
Jun 30, 2021 637,000.00
Jun 30, 2021 637,000.00
Mar 31, 2021 590,000.00
Mar 31, 2021 590,000.00
Dec 31, 2020 328,000.00
Dec 31, 2020 328,000.00
Sep 30, 2020 388,000.00
Sep 30, 2020 388,000.00
Jun 30, 2020 393,000.00
Jun 30, 2020 393,000.00
Mar 31, 2020 391,000.00
Mar 31, 2020 391,000.00
Dec 31, 2019 386,000.00
Dec 31, 2019 386,000.00
Sep 30, 2019 331,000.00
Sep 30, 2019 331,000.00
Jun 30, 2019 315,000.00
Jun 30, 2019 315,000.00
Mar 31, 2019 271,000.00
Mar 31, 2019 271,000.00
Dec 31, 2018 233,000.00
Dec 31, 2018 233,000.00
Sep 30, 2018 208,000.00
Sep 30, 2018 208,000.00
Jun 30, 2018 180,000.00
Jun 30, 2018 180,000.00
Mar 31, 2018 179,000.00
Mar 31, 2018 179,000.00
Dec 31, 2017 172,000.00
Dec 31, 2017 172,000.00
Sep 30, 2017 167,000.00
Sep 30, 2017 167,000.00